false 0001809519 0001809519 2022-03-06 2022-03-06





Washington, D.C. 20549









Date of report (Date of earliest event reported): March 6, 2022



GoodRx Holdings, Inc.

(Exact Name of Registrant as Specified in its Charter)




Delaware   001-39549   47-5104396

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)

2701 Olympic Boulevard

Santa Monica, CA 90404

(Address of Principal Executive Offices) (Zip Code)

(855) 268-2822

(Registrant’s telephone number, including area code)


(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Class A Common Stock, $0.0001 par value per share   GDRX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 1.01

Entry into a Material Definitive Agreement.

On March 6, 2022, GoodRx Holdings, Inc. (“GoodRx” or the “Company”), through a wholly-owned subsidiary of the Company, entered into an agreement to acquire all of the outstanding shares of capital stock of vitaCare Prescription Services, Inc. (“vitaCare”) (the “Acquisition”), pursuant to the terms of a Stock Purchase Agreement (the “Purchase Agreement”), by and between the Company, and TherapeuticsMD, Inc., the sole stockholder of vitaCare (the “Seller”).

Under the terms of the Purchase Agreement, the Company has agreed to make an upfront cash payment of $150.0 million, subject to customary adjustments, to the Seller. In addition, the Seller is eligible to receive certain future contingent payments, of up to an aggregate of $7.0 million in cash that may become payable upon the achievement of certain milestone events. The Company has also agreed to establish a management incentive plan under which certain continuing employees would be eligible to receive up to $10 million of additional compensation upon achievement of certain performance milestones.

The Company and the Seller have agreed to customary representations, warranties and covenants in the Purchase Agreement. Subject to certain limitations, the Seller is required to indemnify the Company for losses resulting from any breaches of the Seller’s representations, warranties and covenants made in the Purchase Agreement and certain other matters, secured in part by a customary escrow from a portion of the upfront cash payment.

The Acquisition is expected to close in mid-2022, subject to the satisfaction or waiver of certain customary conditions, including, among others, (i) obtaining applicable regulatory and third party approvals, (ii) the absence of any order or legal requirement that enjoins, restrains or otherwise prevents the consummation of such Acquisition, (iii) the absence of a Material Adverse Effect (as defined in the Purchase Agreement) and (iv) customary conditions regarding the accuracy of the representations and warranties and material compliance by the parties with their respective obligations under the Purchase Agreement.

The Purchase Agreement includes customary termination provisions for both the Seller and Company, whereby the parties may terminate (i) by mutual written consent, (ii) following a permanent legal prohibition on consummating such Transaction, (iii) if the closing of the Transaction has not occurred prior to the outside date set forth in the applicable Purchase Agreement, (iv) if certain regulatory conditions or actions are imposed or taken with respect to the transaction and (v) following a breach by the other party of its representations and warranties or covenants contained in the Purchase Agreement that would result in a failure of a condition to closing of such Transaction, subject to cure rights.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the expected timing of the closing of the Acquisition, if at all. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the satisfaction of the closing conditions of the vitaCare acquisition, risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks associated with the Company’s acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; and the other important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking statements represent management’s estimates as of the date of this Current Report on Form 8-K. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.


Item 7.01.

Regulation FD Disclosure.

The Company issued a press release on March 7, 2022 announcing the Acquisition. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

The information in this Item 7.01 and Exhibit 99.1 is furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and such information shall not be deemed to be incorporated by reference into any of the Company’s filings under the Securities Act or the Exchange Act.


Item 9.01

Financial Statements and Exhibits

(d)    Exhibits





99.1    Press Release dated March 7, 2022.
104    Cover Page Interactive Data File, formatted in inline XBRL.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ Karsten Voermann

Name:   Karsten Voermann
Title:   Chief Financial Officer

Date: March 7, 2022

EX-99.1 2 d306649dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

GoodRx Agrees to Acquire vitaCare, A Tech-Enabled Pharmacy Services Platform

GoodRx expands offering to pharmaceutical manufacturers while helping to improve patient access and adherence to affordable brand drugs

SANTA MONICA, Calif. March 7, 2022 — GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it has entered into a definitive agreement to acquire vitaCare Prescription Services from TherapeuticsMD. VitaCare is a technology and services platform that helps patients navigate key access and adherence barriers for brand medications. Specifically, vitaCare helps patients understand coverage and identify available savings opportunities, and facilitates communications between providers and payors. The platform also offers a seamless path for filling a prescription, primarily through its network of third-party pharmacies. This acquisition will enable GoodRx to help more patients receive their prescriptions in an efficient, affordable, and transparent manner, and stay on their prescribed therapies as long as appropriate.

Only half of the 500 million brand prescriptions written each year are actually filled, based on IQVIA, FDA and DrFirst data. One important reason is because affordability is a huge barrier to access for many people, leading to a lack of medication adherence among patients. Of all of the prescriptions filled in the U.S. last year, CoverMyMeds found 29% of patients experienced a delay in getting their medication because of insurance processes and provider communication delays. With vitaCare, GoodRx believes it will have more tools to help facilitate the prescription process from start to finish, ensuring patients have a clear path to access and afford the brand-name therapies they need. In addition, the acquisition is expected to further strengthen GoodRx’s set of rapidly growing, high-margin Pharma Manufacturer Solutions offerings which span medication awareness, access, and adherence with unique capabilities.

“Over the past decade, GoodRx has helped millions of Americans afford generic medications, but brand medications remain too expensive for too many people,” said Doug Hirsch, co-CEO and co-founder of GoodRx. “Pharma manufacturers want to help patients find affordable options but too many consumers still face affordability challenges or complex reimbursement processes. With vitaCare, we aim to grow our reach and provide new tools for both consumers and providers to help ensure that more patients can access relevant savings programs and navigate prior authorization requirements. We’re excited about the potential to help patients from the point of prescribing through their ongoing refills to ensure they can stay healthy.”

“We couldn’t be more excited to join GoodRx and be part of a team that is working to put affordable healthcare within reach for everyone,” said John Milligan, CEO at vitaCare Prescription Services. “Consumers come to vitaCare looking for a seamless, patient-first experience that will help them get the brand medications they are prescribed. Upon joining the GoodRx team, we hope to expand our network of pharmaceutical manufacturers and put even more therapies within reach for consumers.”

GoodRx has invested in bringing affordable brand drug solutions directly to consumers. Through our Pharma Manufacturer Solutions business, GoodRx works with pharmaceutical manufacturers to boost awareness of savings programs among patients and prescribers directly on our site, improving patient access to these programs and increasing adherence to the brand medications patients need to stay healthy. With GoodRx Health, our online health information site, GoodRx offers a platform where manufacturers can reach large, high-intent audiences contextually relevant to their products. Now, with vitaCare, GoodRx plans to expand its solutions for pharmaceutical manufacturers to help increase access and adherence for patients.

GoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare’s financial performance through 2023. The transaction is expected to close in mid-2022, subject to the satisfaction of customary closing conditions. We expect the transaction to contribute under 1% to our overall revenue and reduce adjusted EBITDA margin by approximately 2% in 2022, assuming the transaction closes mid-year. We expect the business to grow in revenue and profitability in future years, but not materially impact our long-term guidance.

The company will host a live conference call and webcast today at 5:30 a.m. Pacific Time (8:30 a.m. Eastern Time) to address this acquisition.

GoodRx vitaCare Acquisition Conference Call




Monday, March 7, 2022



5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time



https://investors.goodrx.com (live and replay)

Dial-in number:

   (833) 614-1447

Approximately one hour after completion of the live call, an archived version of the webcast will be available on the Company’s investor relations website at https://investors.goodrx.com for at least 30 days.


Locust Walk, a global life-sciences focused investment bank, served as exclusive advisor to TherapeuticsMD, the parent company of vitaCare.

About GoodRx

GoodRx is a leading consumer-focused digital healthcare platform. Our technology delivers strong savings, trusted information and access to care to make healthcare affordable and convenient for all Americans. Since 2011, we have helped consumers save over $35 billion and are one of the most downloaded medical apps over the past decade.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the benefits of the vitaCare acquisition, the expected timing of the closing of the

vitaCare acquisition, if at all, the impact to future financial results from the vitaCare acquisition, our relationships with manufacturers and the services we provide manufacturers. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the satisfaction of the closing conditions of the vitaCare acquisition, risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks associated with the Company’s acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; and the other important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2021, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.



Lauren Casparis



Whitney Notaro


EX-101.SCH 3 gdrx-20220306.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 gdrx-20220306_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 gdrx-20220306_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information
Mar. 06, 2022
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001809519
Document Type 8-K
Document Period End Date Mar. 06, 2022
Entity Registrant Name GoodRx Holdings, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39549
Entity Tax Identification Number 47-5104396
Entity Address, Address Line One 2701 Olympic Boulevard
Entity Address, City or Town Santa Monica
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90404
City Area Code (855)
Local Phone Number 268-2822
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Class A Common Stock, $0.0001 par value per share
Trading Symbol GDRX
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 d306649d8k_htm.xml IDEA: XBRL DOCUMENT 0001809519 2022-03-06 2022-03-06 false 0001809519 8-K 2022-03-06 GoodRx Holdings, Inc. DE 001-39549 47-5104396 2701 Olympic Boulevard Santa Monica CA 90404 (855) 268-2822 false false false false Class A Common Stock, $0.0001 par value per share GDRX NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 118 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d306649d8k.htm d306649dex991.htm gdrx-20220306.xsd gdrx-20220306_lab.xml gdrx-20220306_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d306649d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d306649d8k.htm" ] }, "labelLink": { "local": [ "gdrx-20220306_lab.xml" ] }, "presentationLink": { "local": [ "gdrx-20220306_pre.xml" ] }, "schema": { "local": [ "gdrx-20220306.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 118, "memberCustom": 0, "memberStandard": 0, "nsprefix": "gdrx", "nsuri": "http://goodrx.com/20220306", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d306649d8k.htm", "contextRef": "duration_2022-03-06_to_2022-03-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d306649d8k.htm", "contextRef": "duration_2022-03-06_to_2022-03-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://goodrx.com//20220306/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-22-067001-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-067001-xbrl.zip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